<DOC>
	<DOCNO>NCT02206646</DOCNO>
	<brief_summary>To monitor safety Metalyse速 clinical practice patient acute myocardial infarction period 6 year required Korean authority , follow observation : 1 . Unexpected adverse drug reaction 2 . Frequency nature adverse event ( AEs ) 3 . Factors safety efficacy profile Metalyse速 Injection . Efficacy Metalyse速 also assess .</brief_summary>
	<brief_title>Post Marketing Surveillance Monitor Safety Efficacy Metalyse速 Korean Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>